索马里兰境内流离失所者营地中Pneumosil肺炎球菌多糖结合疫苗(10价PCV)的安全性与覆盖率
在索马里兰境内流离失所者营地,对6周至59月龄儿童开展PCV10-SII接种,并嵌套II期安全性评价。364名接种儿童中,首剂后34名(11%)出现免疫接种后不良事件(AEFI),第二剂后20名婴儿(49%)出现AEFI;检出3例严重不良事件(SAE),调查均未判定与接种有因果关系。运动式接种覆盖率93.4%,两年期间人群覆盖率降至57.1%。
要点
- 6周至59月龄儿童接种PCV10-SII后AEFI发生率较低,最常见为发热(n=36,10%)。
- 检出3例SAE,经调查均未判定与接种有因果关系。
- 运动式接种覆盖率93.4%,两年期间人群覆盖率降至57.1%。
核心结论
- 儿童接种PCV10-SII后出现少量AEFI,运动式接种覆盖率提示索马里兰境内流离失所者对新引入疫苗接受度较高。
研究设计与样本
- 在索马里兰境内流离失所者营地对6周至59月龄儿童接种PCV10-SII,并嵌套II期安全性评价;<1岁儿童接种两剂,1至4岁儿童接种单剂。
- 接种当日及7天后开展AEFI调查,通过包括当地卫生机构每日随访在内的多种方式识别SAE,并用上臂中围评估营养状况。
- 计算运动式接种覆盖率并估算人群覆盖率,共纳入364名接种儿童进行分析。
主要发现
- 364名接种儿童中,2名(<1%)存在营养不良。
- 首剂后34名(11%)儿童出现AEFI,第二剂后20名(49%)婴儿出现AEFI。
- 最常见AEFI为发热(n=36,10%)、食欲下降(n=15,4%)和注射部位皮疹(n=13,4%)。
- 检出3例SAE,经调查均未判定与接种有因果关系。
- 运动式接种覆盖率为93.4%,两年期间人群覆盖率降至57.1%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Pneumococcal conjugate vaccines (PCVs) have substantially reduced pneumococcal morbidity and mortality worldwide, but their use in crisis settings has been limited. Routine immunisation is typically not feasible during a crisis; however,mass-vaccination campaigns with wider age-targeting could effectively protect crisis-affected populations against pneumococcal disease. The 10-valent Pneumosil PCV (PCV10-SII) is currently licensed for use in children aged 6 weeks to 2 years. We conducted a nested phase II evaluation of PCV10-SII safety within a phase IV intervention study measuring the impact of a PCV campaign on pneumococcal carriage. METHODS: We vaccinated children aged 6 weeks to 59 months in a camp for internally displaced persons (IDPs) in Somaliland. Children aged <1 year received two doses of PCV10-SII; children aged 1 to 4 years received a single dose. We administered an adverse event following immunisation (AEFI) survey on the day of vaccination (to document the occurrence of background AEFI-associated symptoms over the preceding week), and seven days later. We identified severe adverse events (SAEs) using several approaches including daily follow-up with the local health facility. We assessed nutritional status using mid-upper arm circumference. We also calculated campaign coverage, and estimated population coverage. RESULTS: Of the 364 vaccinated children included in the analysis, two (<1 %) were malnourished. AEFIs occurred in 34 (11 %) children after their first dose, and in 20 (49 %) infants after their second dose. The most common AEFIs were fever (n = 36, 10 %), decreased appetite (n = 15, 4 %), and a rash at the injection site (n = 13, 4 %). We detected three SAEs. On investigation, none of the SAEs were deemed to be causally associated with vaccination. Campaign coverage was high (93.4 %), while population coverage reduced to 57.1 % over a two-year period. CONCLUSIONS: Vaccination of children PCV10-SII resulted in a small number of AEFIs. Campaign coverage suggests high acceptability of a newly introduced vaccine amongst IDPs in Somaliland. TRIAL REGISTRATION: NCT04945681.
引用
- McGowan CR, van Zandvoort K, Ibrahim SA, et al. Safety and coverage of Pneumosil pneumococcal polysaccharide conjugate vaccine (10-valent PCV) in a camp for internally displaced persons in Somaliland. Vaccine. 2025. PMID: 41265006. doi:10.1016/j.vaccine.2025.127991
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。